Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03554408
Recruitment Status : Active, not recruiting
First Posted : June 13, 2018
Last Update Posted : April 13, 2020
Sponsor:
Information provided by (Responsible Party):
Rockefeller University

Brief Summary:
This first clinical study of 10-1074-LS will evaluate its safety, tolerability and pharmacokinetics profile when administered alone or in combination with 3BNC117-LS to HIV (human immunodeficiency virus) -infected and HIV-uninfected individuals.

Condition or disease Intervention/treatment Phase
Human Immunodeficiency Virus Drug: 10-1074-LS Drug: 3BNC117-LS Phase 1

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 75 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Masking Description: Groups 1A, 1B, 4A, and 4B are double-blinded; All other arms are open label.
Primary Purpose: Prevention
Official Title: A Phase 1, Dose Escalation, First-in-human Study of the Safety and Pharmacokinetics of the Subcutaneous and Intravenous Administration of 10-1074-LS Alone and in Combination With 3BNC117-LS in HIV-infected and HIV-uninfected Individuals
Actual Study Start Date : June 20, 2018
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : June 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Experimental: Group 1A
HIV-uninfected individuals will be administered one 1 mL (approximately 150 mg) subcutaneous injection of 10-1074-LS or placebo (formulation buffer), in a 3:1 ratio.
Drug: 10-1074-LS
Subcutaneous injection of 10-1074-LS
Other Name: Monoclonal antibody

Experimental: Group 1B
HIV-uninfected individuals will be administered one 2 mL (approximately 300 mg) subcutaneous injection of 10-1074-LS or placebo (formulation buffer), in a 3:1 ratio.
Drug: 10-1074-LS
Subcutaneous injection of 10-1074-LS
Other Name: Monoclonal antibody

Experimental: Group 2A
HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS dosed at 3 mg/kg.
Drug: 10-1074-LS
Intravenous infusion of 10-1074-LS
Other Name: Monoclonal antibody

Experimental: Group 2B
HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS dosed at 10 mg/kg.
Drug: 10-1074-LS
Intravenous infusion of 10-1074-LS
Other Name: Monoclonal antibody

Experimental: Group 2C
HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS dosed at 30 mg/kg.
Drug: 10-1074-LS
Intravenous infusion of 10-1074-LS
Other Name: Monoclonal antibody

Experimental: Group 3B
HIV-infected individuals (on ART) will be administered one intravenous infusion of 10-1074-LS dosed at 10 mg/kg
Drug: 10-1074-LS
Intravenous infusion of 10-1074-LS
Other Name: Monoclonal antibody

Experimental: Group 3C
HIV-infected individuals (on ART) will be administered one intravenous infusion of 10-1074-LS dosed at 30 mg/kg.
Drug: 10-1074-LS
Intravenous infusion of 10-1074-LS
Other Name: Monoclonal antibody

Experimental: Group 4A
HIV-uninfected individuals will be administered one 2 mL (approximately 150 mg of each mAb) subcutaneous injection of 10-1074-LS admixed with 3BNC117-LS or placebo (formulation buffer), in a 3:1 ratio.
Drug: 10-1074-LS
Subcutaneous injection of 10-1074-LS
Other Name: Monoclonal antibody

Drug: 3BNC117-LS
Subcutaneous injection of 3BNC117-LS
Other Name: Monoclonal antibody

Experimental: Group 4B
HIV-uninfected individuals will be administered two 2 mL (approximately 300 mg of each mAb) subcutaneous injections of 10-1074-LS admixed with 3BNC117-LS or placebo (formulation buffer), in a 3:1 ratio.
Drug: 10-1074-LS
Subcutaneous injection of 10-1074-LS
Other Name: Monoclonal antibody

Drug: 3BNC117-LS
Subcutaneous injection of 3BNC117-LS
Other Name: Monoclonal antibody

Experimental: Group 5
HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS and one intravenous infusion of 3BNC117-LS, each dosed at 30 mg/kg.
Drug: 10-1074-LS
Intravenous infusion of 10-1074-LS
Other Name: Monoclonal antibody

Drug: 3BNC117-LS
Intravenous infusion of 3BNC117-LS
Other Name: Monoclonal antibody

Experimental: Group 6
HIV-infected individuals (on ART) will be administered one intravenous infusion of 10-1074-LS and one intravenous infusion of 3BNC117-LS, each dosed at 30 mg/kg.
Drug: 10-1074-LS
Intravenous infusion of 10-1074-LS
Other Name: Monoclonal antibody

Drug: 3BNC117-LS
Intravenous infusion of 3BNC117-LS
Other Name: Monoclonal antibody

Experimental: Group 7
HIV-uninfected individuals will be administered three subcutaneous injections of 10-1074-LS (100 mg) admixed with 3BNC117-LS (200 mg) (2 mL) at weeks 0, 12, and 24.
Drug: 10-1074-LS
Subcutaneous injection of 10-1074-LS
Other Name: Monoclonal antibody

Drug: 3BNC117-LS
Subcutaneous injection of 3BNC117-LS
Other Name: Monoclonal antibody

Experimental: Group 8
HIV-infected individuals (on ART) will be administered three subcutaneous injections of 10-1074-LS (75 mg) admixed with 3BNC117-LS (225 mg) (2 mL) at weeks 0, 12, and 24.
Drug: 10-1074-LS
Subcutaneous injection of 10-1074-LS
Other Name: Monoclonal antibody

Drug: 3BNC117-LS
Subcutaneous injection of 3BNC117-LS
Other Name: Monoclonal antibody

Experimental: Group 9
HIV-infected individuals (on ART) will be administered three subcutaneous injections of 10-1074-LS (60 mg) admixed with 3BNC117-LS (250 mg) (2 mL) at weeks 0, 12, and 24.
Drug: 10-1074-LS
Subcutaneous injection of 10-1074-LS
Other Name: Monoclonal antibody

Drug: 3BNC117-LS
Subcutaneous injection of 3BNC117-LS
Other Name: Monoclonal antibody




Primary Outcome Measures :
  1. The number of participants who experience adverse events within 2 weeks after 10-1074-LS intravenous infusions and subcutaneous injections. [ Time Frame: 2 weeks ]
    Adverse events include signs, symptoms and laboratory abnormalities, in addition to local and systemic reactogenicity adverse events.

  2. The number of participants who experience adverse events within 2 weeks after 10-1074-LS and 3BNC117-LS intravenous infusions and subcutaneous injections. [ Time Frame: 2 weeks ]
    Adverse events include signs, symptoms and laboratory abnormalities, in addition to local and systemic reactogenicity adverse events.

  3. Elimination half-life (t1/2) of 10-1074-LS, when administered alone and in combination with 3BNC117-LS in all study groups. [ Time Frame: 48-72 weeks ]
    Elimination half-life (t1/2) of 10-1074-LS, when administered alone and in combination with 3BNC117-LS in all study groups.

  4. The clearance (CL) of 10-1074-LS, when administered alone and in combination with 3BNC117-LS in all study groups. [ Time Frame: 48-72 weeks ]
    The clearance (CL) of 10-1074-LS, when administered alone and in combination with 3BNC117-LS in all study groups.

  5. The volume of distribution (Vz) of 10-1074-LS, when administered alone and in combination with 3BNC117-LS in all study groups [ Time Frame: 48-72 weeks ]
    The volume of distribution (Vz) of 10-1074-LS, when administered alone and in combination with 3BNC117-LS in all study groups

  6. Area under the curve of 10-1074-LS, when administered alone and in combination with 3BNC117-LS in all study groups. [ Time Frame: 48-72 weeks ]
    Area under the curve of 10-1074-LS, when administered alone and in combination with 3BNC117-LS in all study groups.

  7. Decay curve of 10-1074-LS, when administered alone and in combination with 3BNC117-LS in all study groups. [ Time Frame: 48-72 weeks ]
    Decay curve of 10-1074-LS, when administered alone and in combination with 3BNC117-LS in all study groups.


Secondary Outcome Measures :
  1. Frequency of induced anti-10-1074-LS antibodies [ Time Frame: 48-72 weeks ]
    Frequency of induced anti-10-1074-LS antibodies

  2. Level of induced anti-10-1074-LS antibodies [ Time Frame: 48-72 weeks ]
    Level of induced anti-10-1074-LS antibodies

  3. Frequency of induced anti-3BNC117-LS antibodies [ Time Frame: 48-72 weeks ]
    Frequency of induced anti-3BNC117-LS antibodies

  4. Level of induced anti-3BNC117-LS antibodies [ Time Frame: 48-72 weeks ]
    Level of induced anti-3BNC117-LS antibodies

  5. The number of participants that experience who experience adverse events during the study follow up period after 10-1074-LS and/or 3BNC117-LS administration in all study groups. [ Time Frame: 48-72 weeks ]
    Adverse events include signs, symptoms and laboratory abnormalities



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Groups 1A-1B, 2A-2C, 4A-4B, 5, 7, 8, 9 (HIV-uninfected):

  • Males and females, age 18 to 65
  • Amenable to HIV risk reduction counseling and agrees to maintain behavior consistent with low risk of HIV exposure.
  • If sexually active male or female, and participating in sexual activity that could lead to pregnancy, agrees to use two effective methods of contraception (i.e.

condom with spermicide, diaphragm with spermicide, hormone-eluting IUD, hormone-based contraceptive with condom) from 10 days prior to and nine months after 10-1074-LS and/or 3BNC117-LS administration.

- Female study participants of reproductive potential are defined as pre-menopausal women who have not had a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, tubal ligation or salpingectomy). Women are considered menopausal if they have not had a menses for at least 12 months and have a FSH of greater than 40 IU/L or if FSH testing is not available, they have had amenorrhea for 24 consecutive months.

Groups 3B-3C, 6 (HIV-infected):

  • Males and females, age 18 to 65.
  • Confirmed HIV-1 infection.
  • HIV-infected individuals on ART with HIV-1 plasma RNA levels < 50 copies/mL.
  • Current CD4+ T cell count > 300 cells/μl.
  • If sexually active male or female, and participating in sexual activity that could lead to pregnancy or transmission of HIV, agrees to use two effective methods of contraception (i.e. condom with spermicide, diaphragm with spermicide, hormone-eluting IUD, hormone-based contraceptive with condom) from 10 days prior to and nine months after 10-1074-LS and/or 3BNC117-LS administration.

Exclusion Criteria:

Groups 1A-1B, 2A-2C, 4A-4B, 5, 7, 8, 9 (HIV-uninfected):

  • Confirmed HIV-1 or HIV-2 infection.
  • Weight > 110 kg (subcutaneous groups only: 1A-1B, 4A-4B).
  • History of immunodeficiency or autoimmune disease; use of systemic corticosteroids, immunosuppressive anti-cancer, or other medications considered significant
  • Any clinically significant acute or chronic medical condition (such as autoimmune diseases) that in the opinion of the investigator would preclude participation.
  • Within the 12 months prior to enrollment, the participant has a history of sexually transmitted infection.
  • Hepatitis B or C infection as indicated by the presence of Hepatitis B surface antigen (HBsAg) or hepatitis C virus RNA (HCV-RNA) in blood.
  • Laboratory abnormalities in the parameters listed:
  • Absolute neutrophil count ≤ 1,500 cells/μL;
  • Hemoglobin ≤ 11 gm/dL if female; ≤ 12.5 gm/dL if male;
  • Platelet count ≤ 125,000 cells/μL;
  • ALT ≥ 1.25 x ULN;
  • AST ≥ 1.25 x ULN;
  • Alkaline phosphatase ≥ 1.5 x ULN;by the trial physician within the last 6 months.
  • Pregnancy or lactation.
  • Any vaccination within 14 days prior to mAb infusions.
  • Receipt of any experimental HIV vaccine or monoclonal antibody therapy of any kind in the past.
  • History of severe reaction to a vaccine or drug infusion or history of severe allergic reactions.
  • Individuals with known hypersensitivity to any constituent of the investigational products.
  • Receipt of another investigational product currently or within the past 12 weeks, or expected concurrent participation in another study in which investigational products will be administered.

Groups 3B-3C, 6 (HIV-infected):

  • Have a history of AIDS-defining illness within 3 years prior to enrollment.
  • History of systemic corticosteroids, immunosuppressive anti-cancer, or other medications considered significant by the trial physician within the last 6 months.
  • Any clinically significant acute or chronic medical condition (such as autoimmune diseases), other than HIV infection, that in the opinion of the investigator would preclude participation.
  • Hepatitis B or C infection as indicated by the presence of Hepatitis B surface antigen (HBsAg) or hepatitis C virus RNA (HCV-RNA) in blood.
  • Laboratory abnormalities in the parameters listed below:
  • Absolute neutrophil count ≤ 1,000 cells/μl;
  • Hemoglobin ≤ 10 gm/dL;
  • Platelet count ≤ 100,000 cells/μl;
  • ALT ≥ 1.5 x ULN;
  • AST ≥ 1.5 x ULN;
  • Alkaline phosphatase ≥ 1.5 x ULN;
  • Total bilirubin > 1 x ULN;
  • eGFR < 60 mL/min/1.73m2.
  • Pregnancy or lactation.
  • Any vaccination within 14 days prior to MAb infusions.
  • Receipt of any experimental HIV vaccine or monoclonal antibody therapy of any kind in the past.
  • History of severe reaction to a vaccine or drug infusion or history of severe allergic reactions.
  • Individuals with known hypersensitivity to any constituent of the investigational products.
  • Receipt of another investigational product currently or within the past 12 weeks, or expected concurrent participation in another study in which investigational products will be administered.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03554408


Locations
Layout table for location information
United States, New York
The Rockefeller University
New York, New York, United States, 10065
Sponsors and Collaborators
Rockefeller University
Investigators
Layout table for investigator information
Principal Investigator: Marina Caskey, MD The Rockefeller University

Layout table for additonal information
Responsible Party: Rockefeller University
ClinicalTrials.gov Identifier: NCT03554408    
Other Study ID Numbers: YCO-0971
First Posted: June 13, 2018    Key Record Dates
Last Update Posted: April 13, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Rockefeller University:
10-1074-LS
3BNC117-LS
First in Human
Dose Escalation
Additional relevant MeSH terms:
Layout table for MeSH terms
Acquired Immunodeficiency Syndrome
HIV Infections
Immunologic Deficiency Syndromes
Immune System Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Slow Virus Diseases
Antineoplastic Agents, Immunological
Antibodies
Immunoglobulins
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents